News

Article

European patent granted to Iridex Corp on MicroPulse technology

Author(s):

The patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields.

(Image Credit: AdobeStock/yavdat)

(Image Credit: AdobeStock/yavdat)

Iridex Corp announced the award of the European Patent EP 3009093, titled "Laser System with Short Pulse Characteristics and its Methods of Use.”

According to a news release from the company, the patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse® devices that utilize the patented technology.1

"This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," David Bruce, president and CEO of Iridex, said in the news release.

According to the company, the technology delivers a laser system capability for delivering short, controlled-width pulse trains designed to minimize the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond.

Moreover, by employing a diode pump source and a frequency-doubled solid-state visible laser, the system produces a pulsed output with controlled thermal effects, focusing on tissue-specific photoactivation without photocoagulation damage.1

The company also pointed out that its MicroPulse technology also incorporates software and hardware components in its feedback range control system, effectively managing energy fluctuations and enhancing safety during treatments. The technology covers the full laser wavelength range from 520 nm to 615 nm.

According to the news release, the Unitary Patent will be enforced in European countries by members of the Unified Patent Court as well as the United Kingdom.

Reference:
  1. Corporation I. Iridex Corporation Receives European Patent on MicroPulse Technology. GlobeNewswire News Room. Published February 6, 2024. Accessed February 6, 2024. https://www.globenewswire.com/news-release/2024/02/06/2824281/0/en/Iridex-Corporation-Receives-European-Patent-on-MicroPulse-Technology.html

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.